Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07460232
EARLY_PHASE1

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

The purpose of this research is to evaluate the performance \[sensitivity, specificity, accuracy\] of FET PET/CT imaging to detect ACTH-secreting pituitary adenoma, using operative findings and histopathology as truth standard.

Official title: 18Fluoro-O-(2) Fluoroethyl-L-tyrosine (FET) PET For Localization Of Pituitary Adenomas In Patients With Cushing Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2026-04

Completion Date

2028-07

Last Updated

2026-03-10

Healthy Volunteers

No

Interventions

DRUG

Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET

Patients will receive intravenous administration of radiolabeled FET (5mCi ±10%) administered 20 minutes (±10minutes) prior to the initiation of the attenuation correction CT followed by the PET acquisition encompassing the participant's head/neck, centered on the pituitary gland.

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States